(Q36522045)

14 August 2017

1 reference

title

Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents (English)

1 reference

14 August 2017

0 references

Michael Murray

1

1 reference

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

Journal of Pharmacy and Pharmacology

14 August 2017

published in

1 reference

14 August 2017

volume

58

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

871-885

1 reference

Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Unanticipated plasma concentrations in two clozapine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Identification of a novel splice-site mutation in the CYP1A2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Efficacy of atypical antipsychotics in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Pharmacokinetics of clozapine and risperidone: a review of recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Continuing clozapine treatment despite neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Will routine therapeutic drug monitoring have a place in clozapine therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Omeprazole reduces clozapine plasma concentrations. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Pharmacokinetics of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Therapeutic monitoring of new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Reversible coma caused by risperidone-ritonavir interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Retrospective evaluation of the effect of omeprazole on clozapine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Upregulation of cytochromes P450 2B in rat liver by orphenadrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Drug metabolism and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Pharmacogenetics-based new therapeutic concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Hyperventilation associated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Metabolic drug interactions with new psychotropic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Pharmacokinetic interactions involving clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Humanized xenobiotic response in mice expressing nuclear receptor SXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.7.0001

21 January 2018

Identifiers

DOI

10.1211/JPP.58.7.0001

1 reference

14 August 2017

1 reference